Navigation Links
Northfield Labs Receives FDA Comments

Northfield Laboratories, founded in 1985, is a leading developer of an oxygen-carrying blood substitute. Its product, PolyHeme, is the only blood substitute undergoing clinical trials that has been tested at large enough dosages to be considered a substitute for acute blood loss in trauma and surgical settings. As a result of the process used to manufacture the blood substitute, essentially a solution of polymerized hemoglobin, PolyHeme has a longer shelf life than blood, requires no cross matching and does not transmit disease. //

Northfield Laboratories Inc. reported that it received comments from the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) on its Biologics License Application (BLA), submitted August 2001. CBER indicated that they are seeking additional information before accepting the application for filing and issued a Refusal-to-File letter to the company.

" Refusals for first-time submissions are common,'' said Richard DeWoskin, chief executive officer of Northfield Laboratories Inc. " We are encouraged by the constructive information provided in CBER's initial response, and believe that while the next few months will be busy, there is good reason to expect that modifications resulting from this feedback will help us to progress to the next stage of the application process. The regulatory review will be a multi-stage process. There now will be a period of several weeks during which we will interact with CBER to clarify and come to fully understand the issues in question." said Richard.

The company said the letter included both questions and comments about Northfield's blood substitute, PolyHeme, from CBER. Management said it will quickly begin the process of addressing these issues.
'"/>




Page: 1

Related medicine news :

1. Fifth US Patient Receives Artificial Heart
2. British MPs Say Prostate Cancer Receives Low Priority in the NHS
3. Abbott Receives CE Mark Certification
4. Zactima Receives Fast Track Designation By The FDA
5. East London Receives World Class New Private Hospital Facility
6. Brinda Karat Receives Legal Notice over Ramdev Issue
7. Quake-Hit Pakistan Receives 30 Field Hospitals From Cuba
8. Medtronic’s Insulin Pump Receives Regulatory Approva
9. Aurobindo Receives Approval from USFDA for anti-AIDS drug
10. Sunscreen Blocking UVA Radiation Receives Federal Approval
11. Eddie Thompson Receives Advanced Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Northfield Labs Receives FDA Comments

(Date:8/20/2008)...r-old Contestant Wins Trip to Little League Baseba... The National Spit Tobacco Education,Program (NSTE...st today,and encouraged young baseball players to...ddiction and the health risks of using tobacco pro...year,s slogan contest winner is,Joe Reck, a nine-y...
(Date:8/20/2008)...cently enacted Medicare Improvement Law immediatel...re Advantage insurance companies .../PRNewswire/ -- When the House and Senate,overrode...gislation,protecting Medicare beneficiaries, they ...e Advantage plans during one of the busiest months...
(Date:8/20/2008)...T CREEK, Calif., Aug. 20 /PRNewswire-FirstCall/ --... reported preliminary income from,continuing opera...f $27.5,million, or $0.76 per diluted share, inclu...er diluted share, related to provisions for store,... a 6.8 percent increase,compared with income from ...
(Date:8/20/2008)...FIELD, Mich., Aug. 20 /PRNewswire/ -- WXYZ- TV/Cha...llness Promotion will give thousands of,Detroit me...ALTHY LIVING,FOR KIDS" program. This year the prog....m. to 5 p.m. at the Charles H. Wright Museum of A...77, "Healthy Living for Kids",has provided free im...
Breaking Medicine News(10 mins):Health News:Slogan Contest Educates Young Baseball Players About the Dangers of Tobacco Use 2Health News:Medicare Advantage Plans Struggle to Comply With New Federal Law 2Health News:Longs Drug Stores Corporation Reports Second Quarter Results 2Health News:Longs Drug Stores Corporation Reports Second Quarter Results 3Health News:Longs Drug Stores Corporation Reports Second Quarter Results 4Health News:Longs Drug Stores Corporation Reports Second Quarter Results 5Health News:Longs Drug Stores Corporation Reports Second Quarter Results 6Health News:Longs Drug Stores Corporation Reports Second Quarter Results 7Health News:Longs Drug Stores Corporation Reports Second Quarter Results 8Health News:Longs Drug Stores Corporation Reports Second Quarter Results 9Health News:Longs Drug Stores Corporation Reports Second Quarter Results 10Health News:Longs Drug Stores Corporation Reports Second Quarter Results 11Health News:Longs Drug Stores Corporation Reports Second Quarter Results 12Health News:Longs Drug Stores Corporation Reports Second Quarter Results 13Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 2Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 3
...users of Blackberry email devices on its addictive... the devices could get so addictive that owners mi...ith treatment that is similar to that given to dru...had been carried out by Rutgers University School,...
... fleeting that we could use it in just one tenth o...rch in this area. Researchers say that impressions...vement, because all it needs is just a split secon...decide whether he is worthy of companionship and t...
...st mites in the bedroom can be achieved by replaci...ion, according to a new study.// In “Distribution...urope: The European Community Respiratory Health S...al Institute of Medical Research, Barcelona, Spain...
...ath syndrome has been the cause of many infant dea... sleeps on its back. In a bid to investigate the//..., researchers discovered that infants born with an...were prone to the risk of SIDS. The study has un...
Other Medicine News:Health News:Replacing Old Mattress, Adding Ventilation Reduces Mites 2
(Date:8/18/2008)...fe expectancy for people with,Down syndrome, WASH...world of Down,syndrome, ,Mr. C, is a rarity. A rea...ast 16 years, at seventy, ,Mr. C, has well surpass...wn syndrome, currently in the,late fifties, but in... does,not exhibit clinical symptoms of Alzheimer,s...
(Date:8/18/2008)...n Phase I -, PRINCETON, N.J. and SAN DIEGO, Aug. ...nical stage biotechnology company committed to the...tening and life-altering,infectious diseases, toda...2 by the U.S. Patent and Trademark Office, coverin...in Phase I development for the treatment of HIV-1,...
(Date:8/14/2008)...-- AstraZeneca (NYSE: AZN ),today announced an in...Centre Singapore (NCCS) and the National Universit... The collaboration, which is spelt out in a,Memora... aims to further,build AstraZeneca,s drug developm...ccess to new medicines of potential benefit to pat...
(Date:8/14/2008).../ -- The Clinical Trials,Bootcamp announces its in...nical coordinators, clinical research staff and ot...d in Boca Raton at the Boca Resort from May,14-17t...ators, monitors and,other industry personnel will ...cal trials into a practice, as well as how to take...
Breaking Medicine Technology:Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of 'Mr. C' Causes Major Interest in the Scientific Community 2Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of 'Mr. C' Causes Major Interest in the Scientific Community 3AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 2AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 3AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 4AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 5AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 6Coalition for Pulmonary Fibrosis and American Thoracic Society Continue Research Partnership Through 2010 5549 1Coalition for Pulmonary Fibrosis and American Thoracic Society Continue Research Partnership Through 2010 5549 2Coalition for Pulmonary Fibrosis and American Thoracic Society Continue Research Partnership Through 2010 5549 3Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology 28PCT 29 at Scientific Symposia in Philade 2159 1Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology 28PCT 29 at Scientific Symposia in Philade 2159 2Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology 28PCT 29 at Scientific Symposia in Philade 2159 3Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology 28PCT 29 at Scientific Symposia in Philade 2159 4Studies provide insights into lung disease and lung function in young adults 19977 1Studies provide insights into lung disease and lung function in young adults 19977 2Studies provide insights into lung disease and lung function in young adults 19977 3Crdentia Announces 2008 First Quarter Results 19972 1Crdentia Announces 2008 First Quarter Results 19972 2Crdentia Announces 2008 First Quarter Results 19972 3Crdentia Announces 2008 First Quarter Results 19972 4Crdentia Announces 2008 First Quarter Results 19972 5Crdentia Announces 2008 First Quarter Results 19972 6Crdentia Announces 2008 First Quarter Results 19972 7
... UCB Announces Positive Top-Line Phase III Results... Onset Seizures in,Paediatric Patients from One Mo...gium - April 20, 2007 - UCB today announced,positi...,randomized, multi-centre, placebo-controlled stu...pra® (levetiracetam) (20-50,mg/kg/day) as adju...
...PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 23, 2007 -...ts to date from two separate,Phase 2 clinical tria...ronic kidney disease (CKD) patients. The data show...Hematide could,correct anemia when administered mo...in dialysis patients previously treated with,three...
Other Medicine Technology:UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 2UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 3UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 4UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 5Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month,Hematide for the Treatment of Anemia in Patients with Early- and,End-Stage Chronic Kidney Disease 2Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month,Hematide for the Treatment of Anemia in Patients with Early- and,End-Stage Chronic Kidney Disease 3
Fenestrated 14 mm blades. Wide extension of blade for protection of lids. Self-locking mechanism. Dull finish.
Solid 16 mm blades. Self-locking mechanism. Dull finish.
Infant model. Blades: 7 mm. Solid blades with locking mechanism. Dull finish.
Fenestrated 16 mm blades. Self-locking mechanism. Dull finish.
Medicine Products: